Kinetic parameters of alpha-synuclein seed amplification assay correlate with cognitive impairment in patients with Lewy body disorders

The alpha-synuclein (aSyn) seed amplification assay (SAA) can identify aSyn aggregates as indicator for Lewy body pathology in biomaterials of living patients and help in diagnosing Parkinson´s disease and dementia syndromes. Our objective was to confirm that qualitative results of aSyn SAA are repr...

Full description

Saved in:
Bibliographic Details
Published in:Acta neuropathologica communications 2023-10, Vol.11 (1), p.1-162, Article 162
Main Authors: Bräuer, Stefan, Rossi, Marcello, Sajapin, Johann, Henle, Thomas, Gasser, Thomas, Parchi, Piero, Brockmann, Kathrin, Falkenburger, Björn H
Format: Article
Language:English
Subjects:
Alpha-synuclein
Biological products
Chromatography
Cognitive ability
Dementia
Dementia with Lewy bodies
Development and progression
Disease
Ethylenediaminetetraacetic acid
Laboratories
Medical research
Medicine, Experimental
Normal distribution
Parkinson's disease
Patients
Proteins
RT-QuIC
Sample size
Scientific equipment and supplies industry
Seed amplification assay
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The alpha-synuclein (aSyn) seed amplification assay (SAA) can identify aSyn aggregates as indicator for Lewy body pathology in biomaterials of living patients and help in diagnosing Parkinson´s disease and dementia syndromes. Our objective was to confirm that qualitative results of aSyn SAA are reproducible across laboratories and to determine whether quantitative findings correlate with patient clinical characteristics. Therefore cerebrospinal fluid samples were re-analysed by aSyn SAA in a second laboratory with four technical replicates for each sample. Kinetic parameters derived from each aggregation curve were summarized and correlated with patient characteristics. We found that qualitative findings were identical between the two laboratories for 54 of 55 patient samples. The number of positive replicates for each sample also showed good agreement between laboratories. Moreover, specific kinetic parameters of the SAA showed a strong correlation with clinical parameters, notably with cognitive performance evaluated by the Montreal Cognitive Assessment. We concluded that SAA findings are highly reproducible across laboratories following the same protocol. SAA reports not only the presence of Lewy pathology but is also associated with clinical characteristics. Thus, aSyn SAA can potentially be used for patient stratification and determining the target engagement of aSyn targeting treatments.
ISSN:2051-5960
2051-5960
DOI:10.1186/s40478-023-01653-3